GB0108876D0 - Organic Compounds - Google Patents

Organic Compounds

Info

Publication number
GB0108876D0
GB0108876D0 GBGB0108876.4A GB0108876A GB0108876D0 GB 0108876 D0 GB0108876 D0 GB 0108876D0 GB 0108876 A GB0108876 A GB 0108876A GB 0108876 D0 GB0108876 D0 GB 0108876D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0108876.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0108876.4A priority Critical patent/GB0108876D0/en
Publication of GB0108876D0 publication Critical patent/GB0108876D0/en
Priority to ARP020101270A priority patent/AR035815A1/es
Priority to AU2002302511A priority patent/AU2002302511B2/en
Priority to PL02363011A priority patent/PL363011A1/xx
Priority to MXPA03009220A priority patent/MXPA03009220A/es
Priority to IL15742802A priority patent/IL157428A0/xx
Priority to CNB028079507A priority patent/CN100469767C/zh
Priority to EP02730122A priority patent/EP1379504B1/en
Priority to KR1020037013161A priority patent/KR100616039B1/ko
Priority to CZ20032723A priority patent/CZ20032723A3/cs
Priority to AT02730122T priority patent/ATE446950T1/de
Priority to DE60234167T priority patent/DE60234167D1/de
Priority to HU0303724A priority patent/HUP0303724A3/hu
Priority to NZ528712A priority patent/NZ528712A/en
Priority to RU2003130642/04A priority patent/RU2296751C2/ru
Priority to ES02730122T priority patent/ES2335393T3/es
Priority to JP2002579437A priority patent/JP4366079B2/ja
Priority to PT02730122T priority patent/PT1379504E/pt
Priority to PCT/EP2002/003871 priority patent/WO2002081449A1/en
Priority to SK1242-2003A priority patent/SK12422003A3/sk
Priority to BR0208741-3A priority patent/BR0208741A/pt
Priority to US10/472,653 priority patent/US20040142920A1/en
Priority to PE2002000282A priority patent/PE20021004A1/es
Priority to CA2439241A priority patent/CA2439241C/en
Priority to ZA200306432A priority patent/ZA200306432B/en
Priority to EC2003004765A priority patent/ECSP034765A/es
Priority to NO20034324A priority patent/NO20034324L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
GBGB0108876.4A 2001-04-09 2001-04-09 Organic Compounds Ceased GB0108876D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB0108876.4A GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds
ARP020101270A AR035815A1 (es) 2001-04-09 2002-04-05 Derivados de piperidina, un proceso para su preparacion, composiciones y combinaciones farmacéuticas que comprenden a dichos derivados
CA2439241A CA2439241C (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
HU0303724A HUP0303724A3 (en) 2001-04-09 2002-04-08 Chemokine receptors inhibitor bipiperidinyl-derivatives and pharmaceutical compositions containing them and process for preparation of the compounds
ES02730122T ES2335393T3 (es) 2001-04-09 2002-04-08 Derivados de bipiperinilo y su uso como inhibidores de receptores de quimiocina.
MXPA03009220A MXPA03009220A (es) 2001-04-09 2002-04-08 Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocina.
IL15742802A IL157428A0 (en) 2001-04-09 2002-04-08 Bipiperidinyl derivatives and their use as chemokine receptor inhibitors
CNB028079507A CN100469767C (zh) 2001-04-09 2002-04-08 联哌啶衍生物及其作为趋化因子受体抑制剂的用途
EP02730122A EP1379504B1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
KR1020037013161A KR100616039B1 (ko) 2001-04-09 2002-04-08 비피페리디닐-유도체 및 이의 케모킨 수용체 억제제로서의 용도
CZ20032723A CZ20032723A3 (cs) 2001-04-09 2002-04-08 Bipiperidinylové deriváty a jejich použití jako inhibitorů chemokinových receptorů
AT02730122T ATE446950T1 (de) 2001-04-09 2002-04-08 Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
DE60234167T DE60234167D1 (de) 2001-04-09 2002-04-08 Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
AU2002302511A AU2002302511B2 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
NZ528712A NZ528712A (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
RU2003130642/04A RU2296751C2 (ru) 2001-04-09 2002-04-08 Производные бипиперидина и фармацевтическая композиция на их основе
PL02363011A PL363011A1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
JP2002579437A JP4366079B2 (ja) 2001-04-09 2002-04-08 ビピペリジニル誘導体およびケモカインレセプターインヒビターとしてのそれらの使用
PT02730122T PT1379504E (pt) 2001-04-09 2002-04-08 Derivados bipiperidinilo e sua utilização como inibidores de receptores de quimioquinas
PCT/EP2002/003871 WO2002081449A1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
SK1242-2003A SK12422003A3 (sk) 2001-04-09 2002-04-08 Bipiperidinylové deriváty, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie ako inhibítorov chemokínových receptorov
BR0208741-3A BR0208741A (pt) 2001-04-09 2002-04-08 Derivados de piperidina
US10/472,653 US20040142920A1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
PE2002000282A PE20021004A1 (es) 2001-04-09 2002-04-08 Derivados de piperidina como inhibidores de la ccr5
ZA200306432A ZA200306432B (en) 2001-04-09 2003-08-19 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors.
EC2003004765A ECSP034765A (es) 2001-04-09 2003-09-11 Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocina
NO20034324A NO20034324L (no) 2001-04-09 2003-09-26 Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0108876.4A GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds

Publications (1)

Publication Number Publication Date
GB0108876D0 true GB0108876D0 (en) 2001-05-30

Family

ID=9912541

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0108876.4A Ceased GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds

Country Status (27)

Country Link
US (1) US20040142920A1 (enExample)
EP (1) EP1379504B1 (enExample)
JP (1) JP4366079B2 (enExample)
KR (1) KR100616039B1 (enExample)
CN (1) CN100469767C (enExample)
AR (1) AR035815A1 (enExample)
AT (1) ATE446950T1 (enExample)
AU (1) AU2002302511B2 (enExample)
BR (1) BR0208741A (enExample)
CA (1) CA2439241C (enExample)
CZ (1) CZ20032723A3 (enExample)
DE (1) DE60234167D1 (enExample)
EC (1) ECSP034765A (enExample)
ES (1) ES2335393T3 (enExample)
GB (1) GB0108876D0 (enExample)
HU (1) HUP0303724A3 (enExample)
IL (1) IL157428A0 (enExample)
MX (1) MXPA03009220A (enExample)
NO (1) NO20034324L (enExample)
NZ (1) NZ528712A (enExample)
PE (1) PE20021004A1 (enExample)
PL (1) PL363011A1 (enExample)
PT (1) PT1379504E (enExample)
RU (1) RU2296751C2 (enExample)
SK (1) SK12422003A3 (enExample)
WO (1) WO2002081449A1 (enExample)
ZA (1) ZA200306432B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209736T2 (de) 2001-07-02 2006-11-02 Astrazeneca Ab Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
CN1688307A (zh) * 2002-10-04 2005-10-26 Ucb公司 4－氨基哌啶衍生物,它们的制备方法和它们作为药物的用途
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
WO2004055011A1 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US20070043079A1 (en) * 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
EP1633737A1 (en) * 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
AU2004285051A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US20090124635A1 (en) * 2005-01-20 2009-05-14 Pfizer Inc. Chemical compounds
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
EP2088860A4 (en) * 2006-12-06 2010-12-22 Genzyme Corp COMPOUNDS FOR BINDING TO A CHEMOKINE RECEPTOR
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
US10952415B2 (en) 2011-03-09 2021-03-23 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
HK1209673A1 (en) * 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
JP2017501164A (ja) 2013-12-19 2017-01-12 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピペリジニルテトラヒドロキノリン類
CA2934134A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
JP2017503783A (ja) 2013-12-19 2017-02-02 バイエル ファーマ アクチエンゲゼルシャフト アドレナリン受容体アルファ２ｃ拮抗薬としての置換されたビピペリジニル誘導体
SG11201604978QA (en) 2013-12-19 2016-07-28 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PL203117B1 (pl) * 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
AU772321B2 (en) * 1999-06-11 2004-04-22 Merck Sharp & Dohme Corp. N-cyclopentyl modulators of chemokine receptor activity
AU2001268607A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Company Piperidine amides as modulators of chemokine receptor activity
MXPA03002263A (es) * 2000-09-14 2003-06-24 Schering Corp Antagonistas de receptor de neuropeptido y y5 de urea sustituidos.
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2439241C (en) 2010-06-08
KR20030087066A (ko) 2003-11-12
CN100469767C (zh) 2009-03-18
PE20021004A1 (es) 2003-01-03
NZ528712A (en) 2005-07-29
IL157428A0 (en) 2004-03-28
AR035815A1 (es) 2004-07-14
JP2004525174A (ja) 2004-08-19
ES2335393T3 (es) 2010-03-26
ZA200306432B (en) 2004-06-04
HUP0303724A2 (hu) 2004-03-01
PL363011A1 (en) 2004-11-15
ATE446950T1 (de) 2009-11-15
PT1379504E (pt) 2010-01-04
SK12422003A3 (sk) 2004-05-04
ECSP034765A (es) 2003-10-28
MXPA03009220A (es) 2004-01-29
NO20034324D0 (no) 2003-09-26
KR100616039B1 (ko) 2006-08-28
DE60234167D1 (de) 2009-12-10
RU2003130642A (ru) 2005-04-10
BR0208741A (pt) 2004-06-22
RU2296751C2 (ru) 2007-04-10
WO2002081449A1 (en) 2002-10-17
CA2439241A1 (en) 2002-10-17
EP1379504B1 (en) 2009-10-28
NO20034324L (no) 2003-09-26
AU2002302511B2 (en) 2005-08-04
CZ20032723A3 (cs) 2003-12-17
CN1501915A (zh) 2004-06-02
HUP0303724A3 (en) 2007-09-28
US20040142920A1 (en) 2004-07-22
JP4366079B2 (ja) 2009-11-18
EP1379504A1 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
GB0103389D0 (en) Organic compounds
GB0108606D0 (en) Organic compounds
GB0108337D0 (en) Organic compounds
GB0103303D0 (en) Organic compounds
GB0108087D0 (en) Organic compounds
GB0107368D0 (en) Organic compounds
GB0103258D0 (en) Organic compounds
GB0101598D0 (en) Organic compounds
GB0102841D0 (en) Organic compounds
GB0107365D0 (en) Organic compounds
GB0107508D0 (en) Organic compounds
GB0109727D0 (en) Organic compounds
GB0108091D0 (en) Organic compounds
GB0108101D0 (en) Organic compounds
GB0104438D0 (en) Organic compounds
GB0106652D0 (en) Organic compounds
GB0102089D0 (en) Organic Compounds
GB0102269D0 (en) Organic compounds
GB0102088D0 (en) Organic compounds
GB0104070D0 (en) Organic compounds
GB0103047D0 (en) Organic Compounds
GB0101993D0 (en) Organic compounds
GB0108089D0 (en) Organic compounds
GB0102839D0 (en) Organic compounds
GB0104072D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)